About the Authors
- Anders Svenningsson
-
* E-mail: anders.svenningsson@neuro.umu.se
Affiliation Dept of Pharmacology and Clinical Neuroscience, Umeå University and University Hospital of Northern Sweden, Umeå, Sweden
- Eva Falk
-
Affiliation BiogenIdec Sweden AB, Upplands Väsby, Sweden
- Elisabeth G. Celius
-
Affiliation Department of Neurology, Oslo University Hospital, Ullevål, Norway
- Siegrid Fuchs
-
Affiliation Department of Neurology, University of Graz, Graz, Austria
- Karen Schreiber
-
Affiliation Department of Neurology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
- Sara Berkö
-
Affiliation BiogenIdec Sweden AB, Upplands Väsby, Sweden
- Jennifer Sun
-
Affiliation BiogenIdec Global Medical Affairs, Boston, Massachusetts, United States of America
- Iris-Katharina Penner
-
Affiliation Department of Cognitive Psychology and Methodology, University of Basel, Basel, Switzerland
- for the TYNERGY trial investigators
-
¶Investigators of the TYNERGY trial are listed in the Acknowledgments.
Competing Interests
Anders Svenningsson has received unconditional research grants, travel support, and lecture honoraria from BiogenIdec AB, MerckSerono, BayerSchering A/G, Sanofi-Genzyme AB, and Baxter AB. Eva Falk is a BiogenIdec employee and holds stock in the company. Elisabeth G. Celius has received unconditional research grants, travel support and lecture honoraria from Biogen Idec, Novartis, MerckSerono, Teva, and Aventis. Siegrid Fuchs has received honoraria for scientific advisory boards and invited lectures for Biogen Idec, Merck Serono Bayer-Schering, Genzyme, and Novartis. Karen Schreiber has reiceved honoraria from BiogenIdec, Novartis, and Allergan. Sara Berkö is a BiogenIdec employee and holds stock in the company. Jennifer Sun is a BiogenIdec employee and holds stock in the company. Iris-Katharina Penner has received research grants from Bayer Switzerland AG and the Swiss Multiple Sclerosis Society and has received honoraria for serving as speaker at scientific meetings, consultant, and as member of scientific advisory boards for Actelion, Bayer Pharma AG, Biogen Idec, Merck Serono, Roche, and Teva Aventis. There are no patents, products in development, or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: AS EF EGC SF KS SB IKP. Performed the experiments: AS EF EGC SF KS SB JS IKP. Analyzed the data: AS EF SB JS IKP. Contributed reagents/materials/analysis tools: AS EF EGC SF KS SB JS IKP. Wrote the paper: AS EF IKP.